Results:
No TCs were detected among negative controls (n=10). TC count (normalized to sample volume analyzed) was compared sample-wise for each replicate (n=20): DEPArray/CTAII count was, on average, 100% (standard deviation = 52%). Enriched mixtures of Her2+ and Her2-TCs spiked in HB samples (n=5), were sorted by DEPArray and recovered into separate tubes. By phenotypical re-analysis no Her2+ cells were detected among the Her2-cell fraction and vice versa, neither were donor WBCs found (100% purity). KRASmutated, A549 cells spiked in HB were enriched and loaded on DEPArray. Individual fractions containing either 1 to 5 tumor cells or donor WBCs were sorted. Whole Genome Amplification (Ampli1™ WGA, Silicon Biosystems), KRAS specific gene amplification and Capillary Electrophoresis sequencing were carried out. TCs successfully amplified showed only mutated KRAS, (WBCs were only wild-type). Duplicate preparations of Her2+/Her2-admixed cells (SKBr3/PC3-9) spiked in HB (n=5) were enriched with CellSearch ® and scanned by CTAII ® before and after DEPArray sorting of Her2+ and Her2-fractions. Sorted fractions re-injected in Veridex cartridges and analyzed with CTAII revealed 100% purity, with no WBCs or wrong type of tumor cells Table 1 Molecular characterization for purity and mutational status Across four Spiking experiments of viable (>90%) KRAS mutated cell lines (SW480 n=2, A549 n=1, mix SW480/A549 n=1) in HB, multiple recoveries (range 12-21 per experiment) of individual cells (n=56), 5 cell batches (n=5), or negative controls (n=8) were carried out. Ampli1™ WGA kit (Silicon Biosystems) products from each tube were DNA-fingerprinted (home-brewn 11 loci multiplex reaction, to confirm cell presence, identity and purity) and KRAS gene-specific amplification products were sequenced (on ABI 3730xl). In 91% (51/56) of single cell recoveries, cell presence was confirmed. The 5 tubes with no signal from STR and KRAS suggests that the cell has been removed during surnatant removal before WGA. All successfully amplified cells matched 100% KRAS mutational status and DNA fingerprint, no signals was detected in negative controls recoveries (buffer only). In the mixed tumor cells experiment, different KRAS mutations (and DNA fingerprints) were detected in different tumor cell recoveries, reflecting cell heterogeneity.
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Summary of results
Cells prepared in Veridex central lab, PA (V-HV); count performed in blind by remote labs: Veridex Enschede, NL (V-EU) and SIlicon Biosystems (SB) with DEPArray. Negative controls (only Healthy donor Blood, n=10), were negative in all platforms (data not shown). For spiking experiments (n=20, Table 1) of TCs (SKBr3), a normalization coefficient (9,26/15=61,7%) is used on Veridex counts to take into account volume effectively analyzed by DEPArray (Main Chamber volume). DEParray/CTAII remote count Ratio = SB/(V-EU)=100%, σ=52%. Average number of TC in remote labs [(SB+V-EU)/2]/(V-HV)=80% due to shipping loss, σ=16%, (<σ(SB/V-EU) due to negative correlation from sample splitting after pooling). 
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